FN1 and diabetic kidney disease: Likewise, in vivo treatment with CTGF-targeting AOs reduced expression and interstitial deposition of ECM constituents, such as fibronectin and collagen I, reduced expression of α-SMA, and ameliorated development of renal fibrogenesis after UUO in rat and mouse models of diabetic nephropathy [127,128].